List view / Grid view
Sean E. Harper is the Executive Vice President, Research and Development at Amgen. Dr. Harper joined Amgen in 2002 as vice president, Development, and has held several leadership roles, including heading the establishment of Amgen’s Medical Sciences capability, a translational medicine group focused on biomarker discovery, development, and integration into early phase clinical studies.
Dr. Harper served as vice president of Global Regulatory Affairs and Safety before assuming the role of senior vice president of Global Development and Corporate Chief Medical Officer. He became executive vice president, Research and Development in February 2012.
Prior to joining Amgen, Dr. Harper was senior director of clinical genomics at Merck Research Laboratories. He attended medical school at the University of California at San Francisco, completed internal medicine and gastroenterology training at the Massachusetts General Hospital, and was a postdoctoral fellow in the laboratory of Phillip A. Sharp at the Massachusetts Institute of Technology.
"The Phase 2 data demonstrate that the primary and secondary…
3 October 2013 | By Amgen
"The Phase 2 data demonstrate that the primary and secondary end points were met..."
"These results further support the primary analysis reported at ASCO…
30 September 2013 | By Amgen
"These results further support the primary analysis reported at ASCO which demonstrated a statistically significant durable response rate..."
Trial evaluated nearly 1,000 patients with metastatic colorectal cancer...
28 September 2013 | By Amgen
Trial evaluated nearly 1,000 patients with metastatic colorectal cancer...
Study links RAS mutations to Vectibix clinical response in patients…
11 September 2013 | By Amgen
Study links RAS mutations to Vectibix clinical response in patients with metastatic colorectal cancer...
First trial to evaluate cardiac myosin activator in patients with…
3 September 2013 | By Amgen
First trial to evaluate cardiac myosin activator in patients with acute heart failure presented at ESC Congress 2013...
Results of analyses presented at ESC Congress 2013...
1 September 2013 | By Amgen
Results of analyses presented at ESC Congress 2013...
Amgen will present new data on omecamtiv mecarbil, a small…
27 August 2013 | By Amgen
Amgen will present new data on omecamtiv mecarbil, a small molecule cardiac myosin activator that is being studied for the treatment of heart failure in collaboration with Cytokinetics...
Amgen obtains US rights to novel EU-approved cardiovascular therapy; Servier…
9 July 2013 | By Amgen
Amgen obtains US rights to novel EU-approved cardiovascular therapy; Servier receives option for omecamtiv mecarbil in Europe...
XGEVA becomes first FDA-approved treatment for this rare disease...
13 June 2013 | By Amgen
XGEVA becomes first FDA-approved treatment for this rare disease...
Study meets primary endpoint of progression-free survival...
12 June 2013 | By Amgen
Study meets primary endpoint of progression-free survival...
Amgen announced detailed results from a pivotal Phase 3 trial...
1 June 2013 | By Amgen
Amgen announced detailed results from a pivotal Phase 3 trial...
Amgen outlined the company's long-term strategy during a Business Review…
7 February 2013 | By Amgen
Amgen outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City...
Results from Pegfilgrastim and Anti-VEGF Evaluation Study...
26 January 2013 | By Amgen
Results from Pegfilgrastim and Anti-VEGF Evaluation Study...
Amgen and Pfizer announced that results from several Enbrel® (etanercept)…
12 November 2012 | By Amgen
Amgen and Pfizer announced that results from several Enbrel® (etanercept) studies...
Data from several Prolia® studies...
14 October 2012 | By Amgen
Data from several Prolia® studies...
